What is Vraylar’s (cariprazine) “loss of exclusivity” or LOE date?
I don’t have AbbVie-specific Vraylar (cariprazine) exclusivity-loss/LOE dates in the information provided here, so I can’t give an accurate date without risking misinformation.
How LOE dates are usually determined for Vraylar in the US
For the US, “LOE date” most often refers to the point when generic/biosimilar competition could become possible because patent and regulatory exclusivities end (commonly tied to Hatch-Waxman patent/Orange Book listings and relevant FDA exclusivity periods). The exact date can vary depending on:
- Whether you mean US regulatory market entry for generics vs. a specific patent list
- Which formulation/strength is covered
- Whether additional “blocking” patents remain listed
Where to find the exact LOE/date for Vraylar (and why you might see different dates)
The most reliable place to confirm an LOE date is the FDA Drugs@FDA / Orange Book record for Vraylar and the associated patent numbers and expiry dates. Many sites also compute “LOE” by aggregating those listed patents plus any exclusivity terms, which can produce multiple dates across sources.
Quick clarifying questions (so I can give the correct date)
1) Do you mean the LOE date for the US market only, or another country (EU/UK/etc.)?
2) Is this for a specific Vraylar presentation (e.g., strengths like 1.5 mg, 3 mg, 4.5 mg, 6 mg) or “Vraylar generally”?
If you share the country and (if applicable) the specific strength/form, I can help you pinpoint the exact LOE/expiry date format you’re looking for and what it means operationally.
Sources
No sources were provided in your message.